What the research found

Researchers identified genetic variants in about 10% of people that appear to impair how their bodies respond to GLP-1 receptor agonists like Ozempic. The variants affect an enzyme called PAM, which chemically modifies GLP-1 and other hormones to make them more potent and longer-lasting. Unexpectedly, people carrying these variants actually produce more circulating GLP-1—yet their bodies don't respond to it effectively, a phenomenon the team calls GLP-1 resistance.

The study combined human blood tests, genetic analysis, and mouse models to reach these conclusions. When people with the PAM variants consumed glucose, they showed elevated GLP-1 levels but slower blood sugar normalisation compared to controls. Mice genetically lacking PAM showed the same pattern: high GLP-1 that failed to slow gastric emptying or control glucose as efficiently as in normal mice. The researchers spent years confirming these counterintuitive findings because the results contradicted their initial hypothesis.

The exact mechanism behind GLP-1 resistance remains unclear. While the team ruled out several possibilities, they have not pinpointed why the hormone becomes ineffective despite being present in higher concentrations. The work focused on blood sugar control; whether these variants affect weight-loss responses to GLP-1 drugs at higher doses requires further investigation.

Why it matters for you

If you're tracking blood glucose response or considering GLP-1 use for metabolic optimisation, knowing your PAM genotype could help predict whether you'll be a strong responder. Someone carrying these variants might achieve poorer glucose control on standard GLP-1 doses, leading their clinician to unnecessarily escalate dosing or switch therapies. Genetic screening could short-circuit that trial-and-error phase and point toward alternative approaches sooner—whether that's optimising other medications, adjusting diet timing, or intensifying training protocols.

For those already on GLP-1 therapy tracking fasting glucose, postprandial glucose, or continuous glucose monitor data, flat or sluggish improvements despite compliance could signal underlying GLP-1 resistance rather than poor adherence or lifestyle factors. This reframes how you'd interpret your biomarkers and discuss outcomes with your clinician.

The findings also highlight that hormone physiology is rarely simple. High circulating levels don't guarantee biological activity—tissue responsiveness matters equally. This principle applies beyond GLP-1: high testosterone, high IGF-1, or high cortisol doesn't automatically mean those hormones are doing their job effectively at the receptor level.

Caveats

• PAM variants explain only ~10% of GLP-1 non-response—most people who don't respond well have unknown reasons
• Study focused on blood sugar control in non-diabetic volunteers; weight-loss efficacy in obese or diabetic populations may differ
• Mechanistic cause unknown—the research documents the phenomenon but doesn't explain why high GLP-1 becomes ineffective
• Animal model findings may not fully translate—mice and humans differ in gastric physiology and hormone sensitivity
• Genetic screening for PAM variants is not yet routine clinical practice—availability and cost unknown